Condition: Lung Cancer · Interstitial Lung Disease · Sponsor: David Palma
In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.
This description comes directly from the study's public registry record.
David Palma, MD · 519-685-8650 · david.palma@lhsc.on.ca
Houda Bahig, MD · 514-890-8254 · houda.bahig.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| BC-Cancer Agency - Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| Verspeeten Family Cancer Centre, London Health Sciences Centre | London, Ontario, Canada | Recruiting |
| Centre Hospitalier de l'Universite de Montreal (CHUM) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05986318